Analyst Price Targets — CGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2026 10:07 am | — | Leerink Partners | $5.00 | $2.71 | TheFly | Compugen price target lowered to $5 from $13 at Leerink |
| January 7, 2026 11:08 am | — | H.C. Wainwright | $4.00 | $1.55 | TheFly | Compugen initiated with a Buy at H.C. Wainwright |
| May 21, 2024 7:48 am | Asthika Goonewardene | Truist Financial | $4.00 | $1.74 | TheFly | Compugen price target lowered to $4 from $5 at Truist |
| May 20, 2024 3:43 pm | Stephen Willey | Stifel Nicolaus | $4.00 | $1.74 | StreetInsider | Stifel Reiterates Buy Rating on Compugen (CGEN) |
| May 20, 2024 1:21 pm | Asthika Goonewardene | Truist Financial | $5.00 | $1.74 | StreetInsider | Compugen (CGEN) PT Raised to $5 at Truist Securities |
Latest News for CGEN
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway materially improves its risk-reward profile. A positive randomized readout could help validate COM701, and it would be a win for CGEN's broader PVRIG approach.
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CGEN.
U.S. House Trading
No House trades found for CGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.